Molecular diagnostics for prostate cancer risk and treatment response
MDXHealth operates a multinational molecular diagnostics business focused on prostate cancer, running lab operations in three countries (Belgium, Netherlands, US) with a tech stack centered on lab information systems, Microsoft 365, and cloud infrastructure (AWS/Azure). Current hiring is broad but sparse—one director-level ops role alongside junior and mid-level positions across product, sales, and support—suggesting organizational consolidation rather than aggressive scaling. Active projects center on assay transfer and system validation, while operational pain points (inventory control, equipment management, cost-effective lab scaling) indicate the company is optimizing internal processes.
Notable leadership hires: Operations Director
MDXHealth is a publicly traded molecular diagnostics company providing genetic and epigenetic testing to guide prostate cancer diagnosis, prognosis, and treatment planning for urologists and oncologists. The company operates multinational lab infrastructure—European headquarters in Herstal, Belgium with labs in Nijmegen and Irvine, California—and combines proprietary methylation and next-generation sequencing technologies to deliver actionable molecular data for personalized oncology. The business model spans both direct laboratory operations and pharmaceutical/diagnostic partnerships.
MDXHealth relies on LIMS (lab information systems), Windows/macOS/Linux infrastructure, Microsoft 365 (Teams, SharePoint, OneDrive), Exchange Online, and cloud platforms AWS and Azure for core operations.
European headquarters in Herstal, Belgium; laboratory in Nijmegen, Netherlands; and US headquarters and laboratory in Irvine, California. Current hiring is limited to the United States.
Other companies in the same industry, closest in size